Clinical trials: Hepatobiliary Disorders
NAFLD, MASH
Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease
The goal of this observational study is to establish a unified cohort for retrospective and prospective high quality baseline and follow-up data registration of patients with a diagnosis of NAFLD/NASH/MAFLD, according to…
- Conditions
- NAFLD, MASH, NASH/MASH
- Trial name
- NAFLD Cohort (NCT07051863)
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Fondazione Epatocentro Ticino
Non-Alcoholic Fatty Liver Disease, Obese
Fatty Liver in Obesity: Long-lifestyle Follow-up (FLiO)
Non-alcoholic fatty liver disease (NAFLD) is a condition of excessive hepatic lipid accumulation in subjects that consume less than 20g ethanol per day, without other known causes as drugs consumption or toxins exposure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obese, Overweight
- Trial name
- FLiO (NCT03183193)
- Testing
- Control diet, FLiO diet
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Diabetes Mellitus, Type 2, Metabolic Associated Fatty Liver Disease
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver…
- Trial name
- NCT07663682
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Hospital of Shanxi Medical University
Non Alcoholic Steatohepatitis
The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
To study the effects of synbiotics supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT01791959
- Testing
- synbiotic
- Volunteers
- 54 people
- Sponsor
- National Nutrition and Food Technology Institute
Nonalcoholic Fatty Liver Disease
Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2…
- Trial name
- NCT00633282
- Testing
- Life style intervention, pioglitazone, berberine
- Where
- 3 sites in China
- Volunteers
- 184 people
- Sponsor
- Xin Gao
Esophageal Varices
Cross-section Band Ligation Versus Stepladder Band Ligation of Esophageal Varices
The goal of this randomized controlled trial is to evaluate the cross-section band ligation technique versus the stepladder band ligation technique in esophageal varices prophylaxis.
- Trial name
- NCT06881082
- Testing
- endoscopic band ligation with cross-section technique, Endoscopic band ligation using stepladder technique
- Where
- Egypt
- Volunteers
- 320 people
- Sponsor
- Tanta University
Non-Alcoholic Steatohepatitis (NASH)
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
The primary objective of this study is to characterize the safety, tolerability and dose-limiting toxicities (DLTs) for GR-MD-02 when administered intravenously to subjects with biopsy-proven NASH with advanced liver fibrosis.
- Trial name
- NCT01899859
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Galectin Therapeutics Inc.
Liver Transplant; Complications, NAFLD
Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)
This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.
- Trial name
- NCT03639623
- Testing
- Saroglitazar
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zydus Therapeutics Inc.
Obstructive Sleep Apnea, Metabolic Dysfunction-Associated Steatotic Liver Disease
Association Between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
Association between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
- Trial name
- OSA/MAFLD (NCT07716995)
- Volunteers
- 127 people
- Sponsor
- Assiut University
Non-alcoholic Fatty Liver Disease
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
The primary objective of this trial is to investigate the relative Bioavailability (BA) of tablet formulation of Dabigatran etexilate (DE) with and without co-administration of rabeprazole in healthy male subjects.
- Trial name
- NCT03143166
- Testing
- Dabigatran Etexilate, Rabeprazol sodium
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Non-Alcoholic Fatty Liver Disease
Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease
The worldwide impact of obesity suggests an urgent need for solutions to decrease its burden on modern society. It has been generally understood that obesity is caused by a simple imbalance in the intake of energy in the form of…
- Trial name
- NCT04594954
- Testing
- Diet, FMT, Physical Activity
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-Alcoholic Fatty Liver Disease, Central Obesity
12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat
Obesity and non-alcoholic fatty liver disease (NAFLD) are two related growing epidemics that are becoming pressing public health concerns.
- Trial name
- NCT03912272
- Testing
- High-intensity Interval Training, Usual Care Control
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Quantifying Hepatic Mitochondrial Fluxes in Humans
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Trial name
- NCT05305287
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
NAFLD, Overweight and Obesity
The Role of Dietary Carbohydrate and Fat Availability in the Regulation of Hepatic Lipid Content
The purpose of this study is to investigate dietary compositions effect on liverfat measured by magnetic resonance imaging.
- Conditions
- NAFLD, Overweight and Obesity, Metabolic Syndrome, Diabetes
- Trial name
- LICARB (NCT04581421)
- Testing
- High Carb Low Fat Diet, Low Carb High Fat Diet
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Liver Diseases, Alcoholic, Metabolic Diseases
Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease
Chronic alcoholic and metabolic liver diseases are the two main liver diseases in France. The long-term prognosis of these two diseases are not well known because main studies are retrospective and with only alcoholic patients.
- Trial name
- CALMET (NCT01237574)
- Testing
- Intervention according to the standard of care.
- Where
- 36 sites in France
- Volunteers
- 527 people
- Sponsor
- University Hospital, Bordeaux
Candidiasis
Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.
- Trial name
- NCT01202253
- Testing
- anidulafungin
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Pfizer
Hepatic Ischemia-reperfusion Injury, Non-alcoholic Fatty Liver Disease
Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD
To better understand the occurrence of hepatic ischemia-reperfusion injury (IRI) in patients with non-alcoholic fatty liver disease (NAFLD) and the role of macrophage polarization in this process, this study will retrospectively…
- Trial name
- NCT06950710
- Testing
- NAFLD
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhifeng Gao
Chronic Liver Disease
Colesevelam Versus Placebo in Cholestatic Pruritus
38 patients with pruritus due to chronic cholestatic liver disease will be evaluated in an investigator initiated, multicenter, double-blind, placebo-controlled, 3-week study assessing the effects of colesevelam on pruritus.
- Trial name
- COPE (NCT00756171)
- Testing
- colesevelam
- Where
- 3 sites in Netherlands
- Volunteers
- 38 people
- Sponsor
- Foundation for Liver Research
Essential Fatty Acid Deficiency (EFAD)
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care (Intralipid) from 7 up to 90 days to develop Essential Fatty Acid…
- Trial name
- NCT04555044
- Testing
- Clinolipid, Intralipid
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Baxter Healthcare Corporation
Thrombocytopenia Associated With Chronic Liver Disease
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
This is a phase 2, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag for Japanese subjects with thrombocytopenia associated with chronic liver disease.
- Trial name
- NCT02227693
- Testing
- avatrombopag
- Where
- 14 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.